Titan Pharmaceuticals (NASDAQ:TTNP) engaged Maxim Group as its exclusive financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.
Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the company.
In a statement, the company pointed out there can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.
Titan also said that it does not expect to disclose developments about this process unless and until the evaluation of strategic alternatives has been completed or the board of directors has concluded that disclosure is appropriate or legally required.
